1. Annual report 2023
  2. Research
  3. GREMPAL

GREMPAL

Primary Care Research Group in Common Disorders of the Musculoskeletal System

The Research Group on Prevalent Diseases of the Musculoskeletal System in Primary Care (GREMPAL-consolidated group since 2017) is currently led by Daniel Martínez Laguna and is made up of Carlen Reyes Reyes, Meritxell Aivar Blanch, Cristina Carbonell Abella, Maria Antonia Pou and César Diaz Torné.Its already established lines of research are the epidemiology of osteoporosis and osteoarthritis,  fragility fractures and the pharmaco-epidemiology of the most widely used treatments. In addition, it has incorporated new lines of research: gout (Maria Antonia Pou) and rheumatoid arthritis (César Diaz Torné). GREMPAL has continued with national and international collaborations; since 2021, with the Real-World Epidemiology group (IDIAP Jordi gol) through the joint hiring of Carlen Reyes as a postdoctoral researcher. Since 2023, with the University of Oxford with the international study Epidemiology and Burden of Imminent Subsequent Fractures in postmenopausal women? and in the future with the Medicines Unit through a grant from the health research funds of the Carlos III Institute related to vitamin D. César Diaz Torné will open the door to future collaborations with the rheumatology unit of the Hospital de Sant Pau and together with Maria Antònia Pou they will create links with the Department of Rheumatology of the University of Auckland (New Zealand) where they will stay for a few months.

Group projects

R+D+I PROJECTS FUNDED IN COMPETITIVE CALLS FROM ADMINISTRATIONS OR PUBLIC AND PRIVATE ENTITIES

  • Millora en el maneig de la gota a l'atenció primària. Estada al Departament of General Practice and Primary Health Care, University of Auckland. New Zealand. (EST-22/2). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2024. IP: Maria Antònia Pou Giménez.

  • Millora del maneig de la gota en atenció primària. Estada al Departament of General Practice and Primary Health Care, University of Auckland. New Zealand. (COM_EST-22/1). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2024. IP: Maria Antònia Pou Giménez.

CLINICAL STUDIES

  • Validació del diagnòstic de gota en la base de dades de la història clínica informatitzada de l'Atenció Primària. ICS - Institut Català de la Salut. 2022 IP: Maria Antònia Pou Giménez.

  • Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022 IP: Carlen Reyes Reyes.

  • Preliminary signal assessment in VigiBase enhanced by longitudinal observational health data: the EHDEN pharmacovigilance use case. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022 IP: Carlen Reyes Reyes.

  • Gota y enfermedad de Parkinson en una población mediterránea urbana: estudio caso-control. 2021 IP: Maria Antònia Pou Giménez.

  • Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023 IP: Carlen Reyes Reyes.

  • Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022 IP: Carlen Reyes Reyes.

  • Coneixement sobre artropatia gotosa dels metges residents de Medicina Familiar i Comunitària de Catalunya. ICS - Institut Català de la Salut. 2023-2024. IP: Maria Antònia Pou Giménez.

  • ¿Cual es el impacto de la gota en el empleo? Un estudio cualitativo mediante entrevistas a personas con gota. 2023-2026. IP: Maria Antònia Pou Giménez.

Group publications

JOURNAL PUBLICATIONS

  • Pou MA, Martinez Laguna D, Estebanez JL, Aivar M, Gayarre R, Conesa A et al. Validation of gout diagnosis in electronic primary care medical records: A population-based study. Jt. Bone Spine. 2023;90(6):105628-105628. PMID:37634875.

  • Raventos B, Fernandez Bertolin S, Aragon M, Voss EA, Blacketer C, Mendez Boo L et al. Transforming the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model and Its Use for COVID-19 Research. Clin. Epidemiol. 2023;15969-986. PMID:37724311.

  • Bennett M, Pistillo A, Recalde M, Reyes C, Freisling H, Duarte Salles T. Time trends in the incidence of cardiovascular disease, hypertension and diabetes by sex and socioeconomic status in Catalonia, Spain: a population-based cohort study. BMJ Open. 2023;13(5): PMID:37225269.

  • Gauffin O, Brand JS, Vidlin SH, Sartori D, Asikainen S, Català M et al. Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study. Drug Saf. 2023;46(12):1335-1352. PMID:37804398.

  • Khera R, Dhingra LS, Aminorroaya A, Li K, Zhou JJ, Arshad F et al. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Med. 2023;2(1): PMID:37829182.

  • LYNF, Flach C, Lysen TS, Markov E, van Ballegooijen H, Rijnbeek P et al. Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends. Drug Saf. 2023;46(4):405-416. PMID:36976448.

  • Jeria Navarro S, Gomez A, Park HS, Calvo Aranda E, Corominas H, Pou MA et al. Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature. Front Med (Lausanne). 2023;91089993-1089993. PMID:36714095.

  • Tan EH, Robinson DE, Joedicke AM, Mosseveld M, Bodkergaard K, Reyes C et al. Drug utilization analysis of osteoporosis medications in seven European electronic health databases. Osteoporosis Int. 2023;34(10):1771-1781. PMID:37436441.

PROCEEDING PAPERS

  • Reyes C, Newby D, Burn E, Raventós B, Duarte Salles T. Trends in the prescription of anti-dementia treatments in Spain and the UK: A large network population-based cohort study. Pharmacoepidemiol. Drug Saf. 2023;32367-367.

  • Rodríguez LG, Poveda JL, Carbonell Abella C, Gimenez M, Torné CD, Nogués Solan X et al. One, two and three-year persistence to osteoporosis treatments in patients with type 2 diabetes mellitus: a population-based cohort study. Aging Clin. Exp. Res. 2023;35281-281.

  • Raventós B, Reyes C, Aragonès E, Newby D, Mayer MA, Prieto Alhambra D et al. Impact of the COVID-19 pandemic on prescription trends of psychotropic medications. Gac. Sanit. 2023;37120-121.

  • Raventos B, Fernández Bertolín S, Weaver J, Blacketer C, Aragón M, Recalde M et al. Establishing and characterizing large COVID-19 cohorts after mapping the information system for research in primary care (SIDIAP) in Catalonia to the OMOP common data model. Pharmacoepidemiol. Drug Saf. 2023;32211-211.

Anar a l'inici